Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol in Type III Gaucher Disease (GD3)
NCT07285369Completed
- Sponsor
- Agyany Pharma
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Ambroxol hydrochloride oral solution in Gaucher disease type 3, sponsored by Agyany Pharma. Primary endpoint: Safety and Tolerability of High-Dose Ambroxol at 18 months. Started Mar 2025; status: completed.
02
Drugs
Ambroxol hydrochloride oral solution
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT07285369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285369.